MustGrow Biologics Corp. press release
BioMedNewsBreaks - MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Secures Patent for Natural Biopesticide Treatment of Stored Produce, Foods
TSXV - TSX Venture Exchange · Canada
MustGrow (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0), an agriculture biotech company focused on providing natural biological protection for high value crops, was recently granted an exclusive patent licensing from the University of Idaho in Moscow, Idaho (https://ibn.fm/EF2NV). According to the update, the patent is in connection with a natural biopesticide mustard-based treatment of stored produce and other foods. The treatment’s potential for sprout suppression of potatoes seems optimally timed, particularly amid increased interest in alternatives to chlorpropham (“CIPC”). The leading agrochemical product used for sprout suppression, CIPC is a critical element of potato storage. However, there are growing regulations to eliminate the chemical, which was banned by the European Union in October. “Alternatives to potato sprout inhibition are in critical need as the U.S. moves towards eliminating CIPC,” said MustGrow’s recently appointed scientific advisor, Dr. Matthew J. Morra, a leading world expert on value-added products derived from oilseeds. “Mustard-derived biopesticides rely on a natural sprout inhibitor that meets the needs of the potato industry without the negative human health consequences of current synthetic sprout inhibitors.”
To view the full article, visit: https://ibn.fm/QDY9M
About MustGrow Biologics Corp
MustGrow is a publicly traded agriculture biotech company focused on providing natural science-based biological solutions for high value crops, including fruits and vegetables. MustGrow has designed and owns a United States EPA-approved natural solution that uses the mustard seed's natural defense mechanism to protect plants from pests and diseases. Over 110 independent tests have been completed, validating MustGrow's safe and effective signature products. The product, in granule format, is EPA-approved across all key U.S. states and by Health Canada's PMRA (Pest Management Regulatory Agency) as a bio-pesticide for high value crops such as in fruit and vegetables. MustGrow has now concentrated a liquid format, TerraMG, which, with regulatory approval, could be applied through standard drip or spray equipment, improving functionality and performance features. For more information, visit the company’s website at www.MustGrow.ca.
NOTE TO INVESTORS: The latest news and updates relating to MGROF are available in the company’s newsroom at http://ibn.fm/MGROF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWireto reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text "STOCKS" to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.